LSV Asset Management Has $24.22 Million Stock Holdings in LivaNova PLC $LIVN

LSV Asset Management lifted its position in LivaNova PLC (NASDAQ:LIVN) by 22.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 538,010 shares of the company’s stock after purchasing an additional 99,512 shares during the quarter. LSV Asset Management owned 0.99% of LivaNova worth $24,221,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in LIVN. Envestnet Asset Management Inc. grew its stake in LivaNova by 6.6% during the first quarter. Envestnet Asset Management Inc. now owns 46,833 shares of the company’s stock worth $1,840,000 after buying an additional 2,901 shares during the last quarter. New York State Common Retirement Fund boosted its holdings in shares of LivaNova by 28.6% in the 1st quarter. New York State Common Retirement Fund now owns 48,290 shares of the company’s stock worth $1,897,000 after acquiring an additional 10,733 shares in the last quarter. CWM LLC boosted its holdings in shares of LivaNova by 52.3% in the 1st quarter. CWM LLC now owns 871 shares of the company’s stock worth $34,000 after acquiring an additional 299 shares in the last quarter. Allianz Asset Management GmbH bought a new stake in LivaNova during the 1st quarter worth approximately $593,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in LivaNova during the 1st quarter valued at $1,063,000. 97.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

LIVN has been the topic of a number of recent analyst reports. Barclays boosted their price objective on LivaNova from $55.00 to $58.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 21st. Mizuho lifted their price target on LivaNova from $65.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of LivaNova in a report on Wednesday, October 8th. The Goldman Sachs Group set a $55.00 price objective on shares of LivaNova and gave the company a “neutral” rating in a research report on Wednesday, October 1st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $64.00 target price on shares of LivaNova in a research report on Wednesday, September 3rd. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, LivaNova presently has a consensus rating of “Moderate Buy” and an average target price of $62.43.

LivaNova Price Performance

Shares of LIVN stock opened at $53.89 on Wednesday. The stock has a 50-day moving average price of $53.52 and a 200 day moving average price of $49.25. The company has a quick ratio of 1.09, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The firm has a market cap of $2.94 billion, a price-to-earnings ratio of -13.85 and a beta of 1.00. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $58.91.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, November 5th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.91 by $0.20. The company had revenue of $357.80 million for the quarter, compared to the consensus estimate of $342.32 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The company’s revenue was up 12.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.90 EPS. LivaNova has set its FY 2025 guidance at 3.800-3.90 EPS. Research analysts expect that LivaNova PLC will post 2.85 EPS for the current year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.